Nectar Lifesciences Limited — Others, 11-07-2025: Shareholders meeting

Nectar Lifesciences Ltd. has announced a board meeting to hold an Extraordinary General Meeting (EGM) to approve three key items: the appointment of Dr. Surulichamy Senthilkumar as a Director liable to retire by rotation and as Whole-time Director (R&D) for three years with a monthly salary of INR 6 lakh plus benefits; the transfer of its active pharmaceutical ingredients and formulations business to Ceph Lifesciences Private Limited via slump sale for INR 1270 Cr; and related authorizations to the Chairman & Managing Director to finalize and execute all necessary documents. The business transfer proceeds are intended for debt repayment, new investments, shareholder rewards, and general corporate purposes. Dr. Senthilkumar brings 17 years of experience in R&D and manufacturing, with five patents to his name. The company reported losses in FY 2024-25 due to inventory markdowns but is undertaking cost reduction and performance improvement measures. Shareholders will vote electronically or in person at the EGM.